Corient Private Wealth LP Acquires New Shares in Becton, Dickinson and Company $BDX

Key Points

• Corient Private Wealth acquired 74,844 shares of Becton, Dickinson and Company in the second quarter, worth approximately $11.3 million. Institutional investors collectively own 86.97% of BDX.
• BDX exceeded quarterly earnings and revenue expectations, reporting $3.23 in EPS and $4.98 billion in revenue, with revenue up 5.4% year over year. The company guided to fiscal 2026 EPS of $12.62–$12.72.
• The company declared a quarterly dividend of $1.05 per share, equivalent to a 2.2% annual yield. Analysts’ consensus rating is “Hold,” with an average price target of $185.67.

Corient Private Wealth LP bought a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 74,844 shares of the medical instruments supplier's stock, valued at approximately $11,326,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Auto Owners Insurance Co lifted its stake in Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company during the second quarter worth $3,721,533,000. State Street Corp increased its holdings in shares of Becton, Dickinson and Company by 0.8% during the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier's stock worth $2,714,871,000 after buying an additional 116,737 shares in the last quarter. First Eagle Investment Management LLC lifted its stake in shares of Becton, Dickinson and Company by 16.5% in the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier's stock valued at $2,260,139,000 after acquiring an additional 1,651,592 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Becton, Dickinson and Company by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier's stock valued at $1,331,165,000 after acquiring an additional 53,884 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $189.71 on Friday. The stock has a market cap of $52.27 billion, a price-to-earnings ratio of 57.14, a P/E/G ratio of 13.36 and a beta of 0.19. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $193.07. The company's fifty day moving average is $166.14 and its 200 day moving average is $160.53. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the company earned $3.68 EPS. Becton, Dickinson and Company's revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Barclays boosted their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a research report on Monday, May 11th. Royal Bank Of Canada increased their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research report on Thursday, August 13th. Citigroup reissued a "buy" rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Jefferies Financial Group restated a "buy" rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Finally, UBS Group began coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a "buy" rating and a $190.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $185.67.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,100 shares of the company's stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,869 shares of company stock valued at $1,994,719 in the last ninety days. Insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source